Atlas Trials

Compare Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera® in LTB Follicular Lymphoma

Clinical trial NCT03976102 · COMPLETED

Trial details

NCT number
NCT03976102
Sponsor
Dr. Reddy's Laboratories Limited
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Follicular Lymphoma
Start date
2019-05-15
Primary completion
2022-09-28
Enrollment
317

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.